KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Acquisitions & Divestments: 2009-2024

Historic Change in Acquisitions & Divestments for Arbutus Biopharma (ABUS) over the last 8 years, with Dec 2024 value amounting to $164.6 million.

  • Arbutus Biopharma's Change in Acquisitions & Divestments rose 45.61% to $41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.1 million, marking a year-over-year increase of 22.01%. This contributed to the annual value of $164.6 million for FY2024, which is 24.47% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Change in Acquisitions & Divestments of $164.6 million as of FY2024, which was up 24.47% from $132.3 million recorded in FY2023.
  • Arbutus Biopharma's 5-year Change in Acquisitions & Divestments high stood at $164.6 million for FY2024, and its period low was $56.0 million during FY2022.
  • In the last 3 years, Arbutus Biopharma's Change in Acquisitions & Divestments had a median value of $132.3 million in 2023 and averaged $117.6 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first dropped by 20.40% in 2022, then spiked by 136.20% in 2023.
  • Arbutus Biopharma's Change in Acquisitions & Divestments (Yearly) stood at $73.4 million in 2020, then declined by 4.15% to $70.3 million in 2021, then declined by 20.40% to $56.0 million in 2022, then surged by 136.20% to $132.3 million in 2023, then rose by 24.47% to $164.6 million in 2024.